These findings suggest that the antitumor activity of αMSLN is partially dependent on CD3+CD8+ T cells, highlighting its potential as a novel strategy to enhance the immunotherapeutic efficacy for pancreatic cancer patients. Here, CD8A is linked to pancreatic neoplasm.